Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16299516 | 0.89 | APP (0.48) | MEN1KMT2AELANEAPP | |
| SCHEMBL6937289 | 0.86 | KMT2A (0.48) | MEN1KMT2ATPMTCA1CA2 | |
| SCHEMBL13970432 | 0.82 | GAA (0.56) | MEN1KMT2ACA1CA2RAB9A | |
| SCHEMBL7871721 | 0.82 | TPMT (0.48) | TPMTCA1CA2CA9RXRA | |
| SCHEMBL6391243 | 0.81 | ELANE (0.68) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL177167 | 0.80 | LMNA (0.64) | MEN1KMT2ARAB9AELANELMNA | |
| SCHEMBL3150776 | 0.80 | KMT2A (0.52) | MEN1KMT2ATPMTCA1CA2 | |
| SCHEMBL8315899 | 0.80 | TPMT (0.41) | TPMTCA1CA2CA9RXRA | |
| SCHEMBL18464704 | 0.80 | EPHX2 (0.42) | MEN1KMT2ATPMTCA1CA2 | |
| SCHEMBL24361156 | 0.78 | TPMT (0.44) | TPMTCA1CA2CA9RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6320016-B1 | X-RAY DETECTABLE ARTICLE MOLDED FROM THERMOPLASTIC COMPOSITION; TOY, MEDICAL EQUIPMENT SUCH AS TUBES, JOINT PARTS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-20 | — | — | US | claimed |
| EP-4519340-B1 | PROCESS FOR PREPARING A POLYCARBONATE BY METAL CATALYZED CROSS COUPLING | COVESTRO DEUTSCHLAND AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| EP-4519340-A1 | PROCESS FOR PREPARING A POLYCARBONATE BY METAL CATALYZED CROSS COUPLING | Covestro Deutschland AG (DE) | 2025-03-12 | — | — | EP | disclosed |
| CN-119137182-A | Method for producing polycarbonates by metal-catalyzed cross-coupling | 科思创德国股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2023213745-A1 | PROCESS FOR PREPARING A POLYCARBONATE BY METAL CATALYZED CROSS COUPLING | COVESTRO DEUTSCHLAND AG (DE) | 2023-11-09 | — | — | WO | disclosed |
| US-10597340-B2 | Synthesis of fluorinated radiopharmaceuticals via electrochemical fluorination | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-24 | — | — | US | disclosed |
| US-20160237027-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | HOPE CITY (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160137567-A1 | SYNTHESIS OF FLUORINATED RADIOPHARMACEUTICALS VIA ELECTROCHEMICAL FLUORINATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-05-19 | — | — | US | disclosed |
| US-6320016-B1 | X-RAY DETECTABLE ARTICLE MOLDED FROM THERMOPLASTIC COMPOSITION; TOY, MEDICAL EQUIPMENT SUCH AS TUBES, JOINT PARTS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-20 | — | — | US | disclosed |
| US-4175544-A | X-RAYS OF BODY FOR MEDICAL DIAGNOSIS | Lafayette Pharmacal Inc. (US) | 1979-11-27 | — | — | US | disclosed |
| US-4175544-A | X-RAYS OF BODY FOR MEDICAL DIAGNOSIS | Lafayette Pharmacal Inc. (US) | 1979-11-27 | — | — | US | disclosed |
| US-4022814-A | Iodine containing organic carbonates for use as radiographic agents | LAFAYETTE PHARMACAL, INC. (US) | 1977-05-10 | — | — | US | disclosed |
| US-4022814-A | Iodine containing organic carbonates for use as radiographic agents | LAFAYETTE PHARMACAL, INC. (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597340-B2 | Synthesis of fluorinated radiopharmaceuticals via electrochemical fluorination | SLC18A2, SLC18A3, FES | MEN1 369/4885KMT2A 1318/4885TPMT 2784/4885 |
| US-20160237027-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | MEN1 3778/4885KMT2A 57/4885TPMT 3988/4885 |
| US-20160137567-A1 | SYNTHESIS OF FLUORINATED RADIOPHARMACEUTICALS VIA ELECTROCHEMICAL FLUORINATION | SLC18A2, SLC18A3, FES | MEN1 369/4885KMT2A 1318/4885TPMT 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.